Senseonics (NYSE:SENS) said yesterday that Humana is now providing coverage for its Eversense continuous glucose monitoring system and insertion procedure.
Humana is the fifth-largest health insurer in the U.S. with 17 million patients in 50 states, Washington, D.C. and Puerto Rico, according to a news release. Its coverage policy with Senseonics makes patients with Type 1 and Type 2 diabetes that require insulin eligible for Eversense. The policy was made effective on October 22.
Get the full story at our sister site, Drug Delivery Business News.
